Clinical Trials Logo

Filter by:
NCT ID: NCT03709875 Not yet recruiting - Stroke Clinical Trials

Telerehabilitation in Severe Acquired Brain Injury

Start date: November 26, 2018
Phase: N/A
Study type: Interventional

We will investigate the use of TR, based on advanced Information and Communication Technology (ICT) solutions, taking into account that the supervision of rehabilitation at home will be enriched with the counselling and vital parameters monitoring. The aim of the study is to evaluate that TR is at least non-inferior in comparison with the same amount of usual territorial rehabilitative physical treatments (UTRT), taking into account patients' functional recovery, psychological well-being, caregiver burden, and healthcare costs. The enrolled patients will be balanced for pathology and randomized in two groups, performing TR (G1) or standard rehabilitation training (G2), respectively, according to a pc-generated random assignment.TR will be delivered by means of an advanced video-conferencing system, whereas the patient will be provided with low-cost monitoring devices, able to collect data about his/her health status and QoL. In both the groups each treatment (either cognitive or motor, or both as per patient functional status) will last about one hour a day, five days/week, for 12 weeks. Two structured telephone interviews will be administered to the patients (when possible) and/or their caregivers, and to all the healthcare professionals involved in the patient management, one week after the beginning and at the end of the TR.

NCT ID: NCT03709680 Active, not recruiting - Solid Tumors Clinical Trials

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Start date: May 24, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults with recurrent or refractory solid tumors (phase 1). Neuroblastoma tumor specific cohort to further evaluate antitumor activity of palbociclib in combination with topotecan and cyclophosphamide in children, adolescents, and young adults with recurrent or refractory neuroblastoma. Phase 2 to learn about the efficacy of palbociclib in combination with irinotecan and temozolomide when compared with irinotecan and temozolomide alone in the treatment of children, adolescents, and young adults with recurrent or refractory Ewing sarcoma (EWS).

NCT ID: NCT03709628 Completed - Crohn Disease Clinical Trials

A Study of a FimH Blocker, EB8018, in Crohn's Disease Patients

EBFIM117
Start date: March 7, 2018
Phase: Phase 1
Study type: Interventional

Enterome small molecule drug EB8018 is a first-in-class FimH blocker to be studied in Crohn's disease patients. The proposed indication for EB8018, as an add-on therapy, will be the treatment of adult patients suffering from Crohn's disease.

NCT ID: NCT03709264 Active, not recruiting - Cardiac Surgery Clinical Trials

Intravenous Amino Acid Therapy for Kidney Protection in Cardiac Surgery.

PROTection
Start date: October 7, 2019
Phase: Phase 3
Study type: Interventional

To date, no pharmacological agents are proven efficacious in treating perioperative AKI. There is a strong biological rationale for the administration of amino acid in the management of patients at risk of AKI with increases in renal blood flow and GFR of 25 to 60% for several hours after the administration of amino acids (Woods LL 1993) mediated by a afferent arteriolar dilation.(Meyer TW 1983) Moreover, animal models have demonstrated that an increase in renal blood flow in response to a short-term amino acid infusion can protect the kidney from acute ischemic insults. Finally, these nephro-protective effects are preserved in critical illness. Cardiac surgery appears to be the best setting to test the likely beneficial renal effects of amino acid because of pathophysiological principles and the ability to intervene before the injury has begun. Although the etiology of AKI in cardiac surgery is multifactorial, renal hypoperfusion is believed to play a major role in this development by decreasing renal perfusion through a reduction in renal blood flow and through the activation of the sympathetic nervous system and the renin-angiotensin system with afferent arteriolar vasoconstriction. In this setting, a global increase in renal blood flow by means of Amino Acid therapy appears a logical and promising intervention. The primary aim of the study is to determine whether providing continuous infusion of a balanced mixture of amino acids, compared to placebo (balanced crystalloid solution), reduces the incidence of acute kidney injury (AKI) in patients scheduled for cardiac surgery defined as KDIGO stage 1 or greater during hospital stay.

NCT ID: NCT03709147 Recruiting - Clinical trials for Advanced LKB1-inactive Lung Adenocarcinoma

Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma

FAME
Start date: October 30, 2018
Phase: Phase 2
Study type: Interventional

Lung adenocarcinoma with inactive LKB1 has emerged as a particularly aggressive form of lung cancer, with poor response to immune checkpoint inhibitors. Recent preclinical evidences have demonstrated that LKB1-inactive lung adenocarcinoma is characterized by specific metabolic vulnerabilities, which make it hypersensitive to energetic crisis. For instance, by inhibiting mitochondrial metabolism and reducing ATP availability to cancer cells, the antidiabetic compound metformin has anticancer activity and prevents acquired resistance to cisplatin in lung adenocarcinoma with inactive LKB1. Similarly to metformin, glucose starvation, which can be recapitulated in vivo by cyclic fasting or fasting-mimicking diet (FMD), can cause metabolic crisis in these neoplasms. In this trial, the investigators will assess for the first time the efficacy of combining standard-of-care platinum-based chemoimmunotherapy with metformin plus/minus FMD in patients with LKB1-inactive, advanced lung adenocarcinoma.

NCT ID: NCT03708900 Recruiting - Cushing's Disease Clinical Trials

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Disease

Start date: April 28, 2021
Phase: Phase 2
Study type: Interventional

Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's disease.

NCT ID: NCT03708861 Withdrawn - HIV Infection Clinical Trials

Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients

Start date: January 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to describe pharmacokinetics of maraviroc (MVC) 300 mg and atazanavir/ritonavir (ATV/r) 200/100 mg QD in HIV-infected stable patients.

NCT ID: NCT03707743 Recruiting - Aortic Dissection Clinical Trials

Registry of Patients With Acute/Subacute Type B Aortic Dissection Treated by Means of the STABILISE Technique (STABILISE)

STABILISE
Start date: October 30, 2018
Phase:
Study type: Observational [Patient Registry]

The aim of the study is to evaluate results of patients treated with the STABILISE technique for acute/subacute aortic dissection. Results and postoperative events are reported in accordance with the current reporting standards for endovascular aortic repair prepared and revised by the Ad Hoc Committee for Standardized Reporting Practices in Vascular Surgery of The Society for Vascular Surgery/American Association for Vascular Surgery

NCT ID: NCT03707119 Completed - Clinical trials for Undergraduate Health Professional Students

Student 4 Best Evidence as a Tool to Improve Evidence-Based Practice Competencies

Start date: January 15, 2018
Phase:
Study type: Observational [Patient Registry]

Objective. The aim of the study was to evaluate the effectiveness of an educational program, based on Students 4 Best Evidence (S4BE) Blog, on Evidence-Based Practice (EBP) competencies (attitudes, knowledge and skills) through an EBP laboratory, in undergraduate students of Physiotherapy. Design. An observational perspective study. Setting. Physiotherapy School of Italian University. Participants. 70 undergraduate physiotherapist students of the first year, of both genders, were included. Mean age was 20.48+/-3.20 years and 66% were male and 34% were female. Interventions. The intervention consisted of the use of S4BE to teach EBP competence. The section S4BE "about" has been used to teach the EBP principles and their key steps and the section S4BE "topics" has been used to teach critical thinking and the clinical practice in rehabilitation for a total of 24 training hours. Main Outcome Measure. The evidence-based practice questionnaire (EBP2Q) has been used to evaluate EBP attitude, knowledge and skills, at the start of laboratory (T0), after 24 training hours (T1) and after 3 months of clinical practice training (follow-up). Statistical analysis was performed with SPSS 17.0 An intra-group analysis has been conducted to verify the improvement during the time. Statistically significant was set at p<0.05.

NCT ID: NCT03707080 Completed - Clinical trials for Hepatocellular Carcinoma

Direct Acting Antiviral-Post Authorization Safety Study

Start date: March 9, 2018
Phase:
Study type: Observational

This is an independent optional sub-study parallel to TARGET-HCC (NCT02954094). The purpose of Direct-Acting Antiviral-Post Authorization Safety Study (DAA-PASS) is to investigate the impact of exposure to direct-acting antivirals (DAAs) on early recurrence of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV)-infected patients following successful HCC treatment interventions.